Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
Zur Ablage hinzufügen
  Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben
Zeitschriftenartikel

Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART

MPG-Autoren
/persons/resource/persons45492

Sing,  Tobias
Computational Biology and Applied Algorithmics, MPI for Informatics, Max Planck Society;

/persons/resource/persons44105

Beerenwinkel,  Niko
Computational Biology and Applied Algorithmics, MPI for Informatics, Max Planck Society;

/persons/resource/persons44907

Lengauer,  Thomas
Computational Biology and Applied Algorithmics, MPI for Informatics, Max Planck Society;

Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte in PuRe verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Lehmann, C., Däumer, M., Bousaad, I., Sing, T., Beerenwinkel, N., Lengauer, T., et al. (2006). Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. Journal of Clinical Virology, 37, 300-304.


Zitierlink: https://hdl.handle.net/11858/00-001M-0000-000F-23FF-7
Zusammenfassung
Background Disease progression in HIV infection has been associated with switch of viral coreceptor usage from CCR5 to CXCR4. Objectives To investigate the relationship between HIV-coreceptor tropism and clinical and virological outcome in 40 heavily pretreated patients over time. Methods Coreceptor phenotype was predicted after sequencing the V3 loop of the HIV glycoprotein 120. Results Coreceptor use was stable during observation time in 87% of patients, and CCR5 tropism was predominant. Viral mutations in the pol gene and clinical parameters were not predictive for coreceptor switching. Conclusions Even in patients with repeated HAART failure, CCR5 antagonists might be a valuable treatment option.